|
Synonyms: ISIS 2302 | ISIS2302
Compound class:
Nucleic acid
Comment: Alicaforsen (ISIS 2302) is a phosphorothioate antisense oligonucleotide (ASO) that targets intercellular adhesion molecule-1 (ICAM-1) mRNA (hybridising to a sequence in the 3' UTR) to reduce ICAM-1 protein synthesis.
Full nucleotide sequence is: all-P-(R)-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl- (3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl- (3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl- (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl- (3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'- deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'- deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P- thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl- (3'→5')-2'-deoxyadenosine |
| No information available. |
Summary of Clinical Use ![]() |
| Alicaforsen (ISIS 2302) was progressed as a clinical candidate with potential to reduce inflammation in Crohn's disease and ulcerative colitis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase 3 Interventional | Ionis Pharmaceuticals, Inc. | ||
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | Phase 3 Interventional | Ionis Pharmaceuticals, Inc. | ||